- Home
- Publications
- Publication Search
- Publication Details
Title
Pathways to Endocrine Therapy Resistance in Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-08-21
DOI
10.3389/fendo.2019.00573
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
- (2018) R J Hartmaier et al. ANNALS OF ONCOLOGY
- Duality of estrogen receptor β action in cancer progression
- (2018) TC Guillette et al. CURRENT OPINION IN PHARMACOLOGY
- HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells
- (2018) Kenji Ohe et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Exosome-Mediated Transfer of Cancer Cell Resistance to Antiestrogen Drugs
- (2018) Svetlana Semina et al. MOLECULES
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
- (2018) Małgorzata Szostakowska et al. BREAST CANCER RESEARCH AND TREATMENT
- Treatment for the endocrine resistant breast cancer: Current options and future perspectives
- (2017) Chun-Yu Liu et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
- (2017) Rinath Jeselsohn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
- (2017) Jennifer M. Giltnane et al. Science Translational Medicine
- ERα36, a variant of estrogen receptor α, is predominantly localized in mitochondria of human uterine smooth muscle and leiomyoma cells
- (2017) Yitang Yan et al. PLoS One
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
- (2016) Sean W Fanning et al. eLife
- Roles for miRNAs in endocrine resistance in breast cancer
- (2015) Penn Muluhngwi et al. ENDOCRINE-RELATED CANCER
- Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
- (2014) Marina Colombo et al. Annual Review of Cell and Developmental Biology
- Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
- (2014) Mirjam C. Boelens et al. CELL
- Exosomes from Drug-Resistant Breast Cancer Cells Transmit Chemoresistance by a Horizontal Transfer of MicroRNAs
- (2014) Wei-xian Chen et al. PLoS One
- Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
- (2013) M. Weiner et al. ANNALS OF ONCOLOGY
- Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
- (2013) Marcelo Madeira et al. BMC CANCER
- Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
- (2013) Shira Peleg Hasson et al. Breast Care
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer
- (2013) L. Magnani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer
- (2013) Wei-xian Chen et al. TUMOR BIOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer
- (2012) Jessica L. L. Robinson et al. Frontiers in Endocrinology
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Oestrogen receptor splice variants in the pathogenesis of disease
- (2009) Siân E. Taylor et al. CANCER LETTERS
- An oestrogen-receptor-α-bound human chromatin interactome
- (2009) Melissa J. Fullwood et al. NATURE
- Nuclear and Cytoplasmic Expression of ER 1, ER 2, and ER 5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients
- (2008) A. M. Shaaban et al. CLINICAL CANCER RESEARCH
- MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer
- (2008) Jian-Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
- (2008) Tyler E. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Epigenomics and breast cancer
- (2008) Pang-Kuo Lo et al. PHARMACOGENOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started